Pacific Biosciences of California, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pacific Biosciences of California, Inc.
Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.
PacBio Unveils TRGT, A Tool For Characterizing Rare Disease
PacBio's TRGT can sequence broader sections of DNA, giving scientists and clinicians better odds of spotting repeated sections of DNA linked to disease.
Stock Watch: Different Regulators Bare Their Teeth At Biotech
When the sector worries about regulation it is usually about drug development and registration. But governments also regulate on monopolistic positions in life sciences. Adding to that, national security enforcement is now rising.
Stock Watch: Biogen, Blood In The Water
When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.
- Research, Analytical Equipment & Supplies
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.